BCD Meetings & Incentives last week launched an EMEA-wide Pharmaceutical Code Compliance Team to reassure clients it operates within the strict requirements governing meetings staged by pharmaceutical ...
UroGen Pharma (URGN) announced that adult patients living with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer now have improved access to an important therapy, as the ...
A recently passed report by the AMA’s Council on Ethical and Judicial Affairs (CEJA) won’t have a significant effect on commercial funding for CME, pharma companies said. “While we don’t expect there ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results